A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Eravacycline (Primary) ; Ertapenem; Levofloxacin
  • Indications Bacterial infections; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNITE3
  • Sponsors Tetraphase Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2017 According to a Tetraphase Pharmaceuticals media release, this study is enrolling more rapidly than expected and we now expect to complete enrollment early in the fourth quarter of 2017.
    • 17 Jan 2017 Status changed from not yet recruiting to recruiting, according to a Tetraphase Pharmaceuticals media release.
    • 17 Jan 2017 According to a Tetraphase Pharmaceuticals media release, first patient has been dosed in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top